Form 4: Vir Biotechnology Director Sells Shares

Vicki L. Sato, a director at Vir Biotechnology, sold 22,000 shares of common stock for a weighted average price of $5.8362 per share under a pre-arranged trading plan.

Summary

• Vicki L. Sato, a Director of Vir Biotechnology, Inc. (VIR), reported a sale of common stock.
• The transaction involved the disposition of 22,000 shares of common stock.
• The shares were sold on October 1, 2025, at a weighted average price of $5.8362 per share.
• The sales were executed pursuant to a Rule 10b5-1 trading plan adopted by Ms. Sato on March 27, 2025.
• Following this transaction, Ms. Sato beneficially owns 1,232,391 shares of common stock directly.
• The selling price ranged from $5.68 to $5.99 per share.

Sentiment

Score: 5

Explanation: The transaction is a routine insider sale conducted under a pre-arranged 10b5-1 plan, which typically reduces the negative perception associated with insider selling. It does not reflect on the company's operational performance or future prospects.

Positives

• The sale was conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a planned and not opportunistic transaction.

Negatives

• A director's sale of shares could be perceived negatively by some investors, though mitigated by the 10b5-1 plan.

Future Outlook

N/A

Industry Context

N/A

Stakeholder Impact

• Shareholders: May note a director's sale, but the 10b5-1 plan mitigates concerns about opportunistic selling.
• Company: No direct operational impact.

Key Dates

Keywords

Vir Biotechnology, VIR, Vicki L. Sato, Insider Trading, Form 4, Stock Sale, Director, 10b5-1 Plan, Equity Transaction